This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns. The regulator is worried about possible drug-induced hepatotoxicity. This comes after the trials may have led to liver enzyme elevations. Biomea Fusion chairman and CEO Thomas Butler said the following about this clinical hold news. How This Affects BMEA Stock Today Investors will want to stick around for even more of the most recent stock market stories on Friday! On the date of publication, William Whi ...

So, how does a shorted stock become a short squeeze stock? It all depends on an unexpected event causing the stock's value to increase, which forces the investors who shorted the stock to buy themselves out of their short positions to mitigate losses. Because these investors exit the position through a buy signal, it causes even more value creation for the stock, creating a short squeeze and spiking the stock. This sharp spike resembles the wavelength of a gamma ray, hence why it is often referred to as a g ...

About COVALENT-111 REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT111 and COVALENT-112), respectively. The Company will continue ongoing safety and e ...

For those seeking blistering returns in a relatively short amount of time, short-squeeze stocks may be the go-to place. Here, contrarians leverage the power of psychology to the extreme, leading to possibly intense fervor. To recap, a short position starts when a speculator borrows shares of the targeted enterprise from a broker. From there, the trader dumps the securities in the hopes of picking them up later at a discount. The aim is to return the borrowed shares back to the broker and pocket the differen ...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT- 111, with a total of over 260 type 2 diabetes patients enrolled. Forward-Looking Statements About CO ...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT111, with a total of over 260 type 2 diabetes patients enrolled. The COVALENT-111 study is a multi-sit ...

Possible short-squeeze targets Source: Barchart The surge in GameStop (NYSE: GME) and AMC Entertainment (NYSE: AMC) stocks, which added over 100% in their value in just one day, has hinted at the craze that was gripping the stock market when meme mania hit and has already caused short-sellers to lose over $1 billion, while GME and AMC stocks added over $6 billion to their market caps in the process. Now, the question is whether this surge is sustainable, whether it can spread to other stocks deemed 'meme st ...

Exhibit 99.1 Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) - Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported first quarter 2024 financial results and corporate highlights. DIABETES • R ...

| --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------|--------------|-------|-------------| | Operating expenses: | | March \n2024 | 31, | 2023 | | Research and development | $ | 33,776 | $ | 24,395 | | General and administrative | | 7,283 | | 5,636 | | Total operating expenses | | 41,059 | | 30,031 | | Loss from operations | | (41,059 ) | | (30,031 ) | | Interest and other income, net | | 1,998 | | 980 | | Net loss | $ | (39,061 ) | $ | (29,051 ) | | Other ...

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's c ...